TNG-260 is under clinical development by Tango Therapeutics and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TNG-260’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TNG-260 overview

TNG-260 is under development for the treatment of STK11 mutated solid tumors like metastatic non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, pancreatic cancer, cervical cancer, breast cancer. It is administered through oral route. It acts by targeting REST corepressor 1 (CoREST). It is being developed based on CRISPR technology.

Tango Therapeutics overview

Tango Therapeutics is a biotechnology company that discovers and develops novel drug targets for the treatment of cancer. The company is investigating TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) against methylthioadenosine phosphorylase (MTAP) deleted cancers. It also develops PRMT5 TNG462 for MTAP-deleted tumors; CoREST TNG260 for STK11-mutant cancers; USP1 TNG348 for BRCA1 and BRCA2-mutant and HRD+ cancers. It works in collaboration with Gilead Sciences to discover, develop, and commercialize cancer therapies. Tango Therapeutics is headquartered in Boston, Massachusetts, the US.

For a complete picture of TNG-260’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.